Anti-FLT3/CD3 DART and anti-FLT3 CAR-T are some of the current specific ‘immune magic bullets’ available in ongoing clinical trials in the R/R FLT3mut AML treatment scenario. This evidence concerns the gene FLT3 and acute myeloid leukemia.